Nkx2-5 Regulates Tdgf1 (Cripto) Early During Cardiac Development

Ann N Behrens1, Yi Ren, Anwarul Ferdous

  • 1Lillehei Heart Institute, University of Minnesota, Minneapolis, Minnesota, USA.

Journal of Clinical & Experimental Cardiology
|September 27, 2013
PubMed

Insights

Understanding congenital heart disease (CHD) requires studying cardiac progenitor cells. Researchers identified Nkx2-5 as a key regulator of the Tdgf1 gene, crucial for early heart development and potentially treating CHD.

Area of Science:

  • Developmental Biology
  • Cardiovascular Research
  • Genetics

Background:

  • Congenital Heart Disease (CHD) is a leading cause of infant mortality.
  • Advanced heart failure is a common progression in CHD survivors, necessitating treatments like cardiac transplantation.
  • Understanding transcriptional networks in cardiac progenitor cells is vital for comprehending heart development and disease.

Purpose of the Study:

  • To define specific transcriptional networks governing cardiovascular development.
  • To investigate the regulatory relationship between Nkx2-5 and Tdgf1 in early cardiac development.
  • To enhance the understanding of cardiac morphogenesis and its pathological states.

Main Methods:

  • Utilized transgenic technology to isolate and characterize cardiac progenitor cells from developing mouse hearts.
  • Employed a range of molecular biological techniques to dissect gene regulation.
  • Confirmed the upstream regulatory role of Nkx2-5 on the Tdgf1 gene.

Main Results:

  • Identified Tdgf1 as a potential target gene regulated by Nkx2-5.
  • Mechanistically confirmed Nkx2-5 as an upstream regulator of Tdgf1 during early cardiac development.
  • Provided insights into Nkx2-5 mediated transcriptional networks in cardiac development.

Conclusions:

  • Nkx2-5 plays a critical role in regulating Tdgf1 during early heart development.
  • These findings contribute to understanding Nkx2-5 mediated transcriptional networks and cardiac morphogenesis.
  • The research has implications for developing novel therapies for congenital heart disease.